The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $22.89

Today's change+1.06 +4.86%
Updated March 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $22.89

Today's change+1.06 +4.86%
Updated March 22 4:00 PM EDT. Delayed by at least 15 minutes.

Nektar Therapeutics up sharply

Nektar Therapeutics closed up sharply Wednesday, rallying (U.S.)$1.06 or 4.86% to (U.S.)$22.89. Over the last five days, shares have gained 45.98% and are currently 2.05% off of the 52-week high. Shares have outperformed the S&P 500 by 61.91% during the last year.

Key company metrics

  • Open(U.S.) $21.83
  • Previous close(U.S.) $21.83
  • High(U.S.) $23.29
  • Low(U.S.) $21.73
  • Bid / Ask(U.S.) $23.28 / (U.S.) $23.62
  • YTD % change+86.55%
  • Volume5,601,914
  • Average volume (10-day)3,379,868
  • Average volume (1-month)2,136,308
  • Average volume (3-month)1,583,883
  • 52-week range(U.S.) $11.41 to (U.S.) $23.37
  • Beta1.71
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.10
Updated March 22 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-92.80%

Although this company's net profit margin is negative, it is above the industry average and implies that Nektar Therapeutics is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.23%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue37363359
Total other revenue--------
Total revenue37363359
Gross profit31292550
Total cost of revenue7789
Total operating expense70697168
Selling / general / administrative13101110
Research & development50525249
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0------
Other operating expenses, total--------
Operating income-32-33-38-9
Interest income (expense), net non-operating-10-11-11-11
Gain (loss) on sale of assets--------
Other--------
Income before tax-42-43-48-19
Income after tax-42-43-49-19
Income tax, total0000
Net income-42-43-49-19
Total adjustments to net income--------
Net income before extra. items-42-43-49-19
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-42-43-49-19
Inc. avail. to common incl. extra. items-42-43-49-19
Diluted net income-42-43-49-19
Dilution adjustment------0
Diluted weighted average shares149137136136
Diluted EPS excluding extraordinary itemsvalue per share-0.28-0.32-0.36-0.14
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.28-0.32-0.36-0.14